|
1
|
Thummarati P, Wijitburaphat S, Prasopthum
A, Menakongka A, Sripa B, Tohtong R and Suthiphongchai T: High
level of urokinase plasminogen activator contributes to
cholangiocarcinoma invasion and metastasis. World J Gastroenterol.
18:244–250. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH,
Shin SM, Song KS, Lee YH, Kim YJ, Lee JJ, Choi I and Lee JH:
Macrophage inhibitory cytokine-1 induces the invasiveness of
gastric cancer cells by up-regulating the urokinase-type
plasminogen activator system. Cancer Res. 63:4648–4655.
2003.PubMed/NCBI
|
|
3
|
Blasi F and Carmeliet P: uPAR: a versatile
signalling orchestrator. Nat Rev Mol Cell Biol. 3:932–943. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
de Bock CE and Wang Y: Clinical
significance of urokinase-type plasminogen activator receptor
(uPAR) expression in cancer. Med Res Rev. 24:13–39. 2004.
View Article : Google Scholar
|
|
5
|
Andreasen PA, Egelund R and Petersen HH:
The plasminogen activation system in tumor growth, invasion, and
metastasis. Cell Mol Life Sci. 57:25–40. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stepanova VV and Tkachuk VA: Urokinase as
a multidomain protein and polyfunctional cell regulator.
Biochemistry (Mosc). 67:109–118. 2002. View Article : Google Scholar
|
|
7
|
Botkjaer KA, Deryugina EI, Dupont DM,
Gårdsvoll H, Bekes EM, Thuesen CK, Chen Z, Ploug M, Quigley JP and
Andreasen PA: Targeting tumor cell invasion and dissemination in
vivo by an aptamer that inhibits urokinase-type plasminogen
activator through a novel multifunctional mechanism. Mol Cancer
Res. 10:1532–1543. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ballance DJ, Marshall JM, Cottingham IR,
Steven J, Berry SJ, Cederholm-Williams SA, Goodey AR and Courtney
M: A hybrid protein of urokinase growth-factor domain and
plasminogen-activator inhibitor type 2 inhibits urokinase activity
and binds to the urokinase receptor. Eur J Biochem. 207:177–183.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rabbani SA, Mazar AP, Bernier SM, Haq M,
Bolivar I, Henkin J and Goltzman D: Structural requirements for the
growth factor activity of the amino-terminal domain of urokinase. J
Biol Chem. 267:14151–14156. 1992.PubMed/NCBI
|
|
10
|
Solberg H, Ploug M, Høyer-Hansen G,
Nielsen BS and Lund LR: The murine receptor for urokinase-type
plasminogen activator is primarily expressed in tissues actively
undergoing remodeling. J Histochem Cytochem. 49:237–246. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li H, Ye X, Mahanivong C, Bian D, Chun J
and Huang S: Signaling mechanisms responsible for lysophosphatidic
acid-induced urokinase plasminogen activator expression in ovarian
cancer cells. J Biol Chem. 280:10564–10571. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ljuca D, Fatusić Z, Iljazović E and
Ahmetović B: Monitoring of chemotherapy successfulness of
platina/taxol chemotherapy protocol by using determination of serum
urokinase plasminogen activator (uPA) and soluble urokinase
plasminogen activator receptor (suPAR) in patients with ovarian
carcinoma FIGO II and III stage. Bosn J Basic Med Sci. 7:111–116.
2007.PubMed/NCBI
|
|
13
|
Kotzsch M, Bernt K, Friedrich K, Luther E,
Albrecht S, Gatzweiler A, Magdolen V, Baretton G, Zietz C and
Luther T: Prognostic relevance of tumour cell-associated uPAR
expression in invasive ductal breast carcinoma. Histopathology.
57:461–471. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ulisse S, Baldini E, Sorrenti S and
D’Armiento M: The urokinase plasminogen activator system: a target
for anticancer therapy. Curr Cancer Drug Targets. 9:32–71. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shin JM, Jeong YJ, Cho HJ, Park KK, Chung
IK, Lee IK, Kwak JY, Chang HW, Kim CH, Moon SK, Kim WJ, Choi YH and
Chang YC: Melittin suppresses HIF-1α/VEGF expression through
inhibition of ERK and mTOR/p70S6K pathway in human cervical
carcinoma cells. PLoS One. 8:e693802013. View Article : Google Scholar
|
|
16
|
Li B, Gu W, Zhang C, Huang XQ, Han KQ and
Ling CQ: Growth arrest and apoptosis of the human hepatocellular
carcinoma cell line BEL-7402 induced by melittin. Onkologie.
29:367–371. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Orsolić N, Sver L, Verstovsek S, Terzić S
and Basić I: Inhibition of mammary carcinoma cell proliferation in
vitro and tumor growth in vivo by bee venom. Toxicon. 41:861–870.
2003. View Article : Google Scholar
|
|
18
|
Raghuraman H and Chattopadhyay A:
Melittin: a membrane-active peptide with diverse functions. Biosci
Rep. 27:189–223. 2007. View Article : Google Scholar
|
|
19
|
Tang J, Li J, Zeng G, Tang Y, Tian W, He
J, York JP and Xia X: Antisense oligonucleotide suppression of
human IGF-1R inhibits the growth and survival of in vitro cultured
epithelial ovarian cancer cells. J Ovarian Res. 6:712013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gajski G and Garaj-Vrhovac V: Melittin: a
lytic peptide with anticancer properties. Environ Toxicol
Pharmacol. 36:697–705. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gurkan C and Ellar DJ: Recombinant
production of bacterial toxins and their derivatives in the
methylotrophic yeast Pichia pastoris. Microb Cell Fact. 4:332005.
View Article : Google Scholar : PubMed/NCBI
|
